Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Osaka, Japan.
Department of Gynecologic Oncology, Cancer Institute Hospital, Tokyo, Japan.
Int J Clin Oncol. 2021 Feb;26(2):417-428. doi: 10.1007/s10147-020-01799-3. Epub 2021 Jan 12.
To evaluate the safety and efficacy of laparoscopic radical hysterectomy (LRH) for cervical cancer, in terms of morbidity and short-term oncologic outcome following LRH's introduction into Japan.
We conducted a retrospective analysis of patients with early-stage cervical cancer (FIGO staging IA2, IB1, and IIA1) who underwent LRH from Dec 2014 to Dec 2016. We assessed the morbidity, overall survival (OS) and recurrence-free survival (RFS), and prognostic factors for RFS.
A total of 251 patients were included from 22 facilities across Japan. There were 8 cases of stage IA2 cervical cancer, 226 of IB1, and 17 of IIA1. The median operating time was 343 min and the median blood loss was 190 ml. Two patients (0.8%) had a postoperative complication with a Clavien-Dindo classification of grade 3 or higher. After a median follow-up time of 15.6 months, the 2-year RFS was 87.4%, and the 2-year OS was 97.8%. When the 2-year RFS rate was compared with whether the patient pathologically had tumors of less than 2 cm, versus 2 cm or more, the RFS was 95.8% and 80.4%, respectively. Multivariate analysis found that tumor size and the route of lymph node removal were independent prognostic factors for recurrence.
When LRH was first introduced into Japan, we found that the route of lymph node removal was an independent prognostic factor for recurrence in addition to large tumors (≥ 2 cm). Our results suggest that prognosis may be secured by paying attention to the lymph node removal route.
评估腹腔镜根治性子宫切除术(LRH)治疗宫颈癌的安全性和疗效,从发病率和 LRH 引入日本后的短期肿瘤学结果方面进行评估。
我们对 2014 年 12 月至 2016 年 12 月期间接受 LRH 治疗的早期宫颈癌(FIGO 分期 IA2、IB1 和 IIA1)患者进行了回顾性分析。我们评估了发病率、总生存率(OS)和无复发生存率(RFS),以及 RFS 的预后因素。
从日本的 22 个医疗机构共纳入了 251 名患者。IA2 期宫颈癌有 8 例,IB1 期 226 例,IIA1 期 17 例。中位手术时间为 343 分钟,中位出血量为 190ml。有 2 例(0.8%)患者术后并发症的 Clavien-Dindo 分级为 3 级或更高。中位随访时间为 15.6 个月后,2 年 RFS 为 87.4%,2 年 OS 为 97.8%。当比较 2 年 RFS 率是否与患者病理肿瘤大小小于 2cm 与大于或等于 2cm 时,RFS 分别为 95.8%和 80.4%。多因素分析发现,肿瘤大小和淋巴结清扫途径是复发的独立预后因素。
当 LRH 首次引入日本时,我们发现除了大肿瘤(≥2cm)外,淋巴结清扫途径也是复发的独立预后因素。我们的结果表明,通过关注淋巴结清扫途径可以确保预后。